1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Centaur Pharma Launches New Generic Cardiac Drug Ivabradine Hydrochloride in US

17 Jul 2024
Admin
News Article

Centaur Pharma Launches New Generic Cardiac Drug Ivabradine Hydrochloride in US

Overview

Centaur Pharmaceuticals, which ranks among India’s few, fully integrated pharmaceutical firms with proficiencies across the pharmaceutical value chain, has launched its generic version of Corlanor (ivabradine hydrochloride) tablets, 5mg and 7.5mg in the United States (US) through its marketing partner Ingenus Pharmaceuticals.

Ivabradine Hydrochloride: Indication

The ANDA ivabradine hydrochloride tablets are indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction.
Annual sale: -Corlanor had annual sales of USD 149 million as of MAT May 2024, according to IQVIA data.

ANDA for Ivabradine Hydrochloride

The ANDA for this ivabradine hydrochloride tablets product received 180-day exclusivity according to the Hatch-Waxman Act from the US Food and Drug Administration (FDA), a status that applies to a first-generic applicant.
Centaur has highlighted that this product is a day one launch, entering the market as a generic equivalent to Corlanor tablets.

Centaur Specialities

Centaur specializes across the pharmaceutical value chain including API, formulations, contract research and manufacturing services, clinical research, R&D, regulatory and marketing. Centaur currently has several products in its active development pipeline.

Centaur Pharmaceuticals

Headquartered in Mumbai, Centaur Pharmaceuticals commenced pharmaceutical manufacturing operations in 1978.
It has now evolved into a vertically integrated pharmaceutical company.
Centaur has a strong matrix of capabilities across the pharmaceutical value chain including API, formulations, contract research and manufacturing services, clinical research, R&D, regulatory and marketing.
With 42 percent of its sales accruing from international markets, Centaur exports to 96 countries across five continents.
With world-class infrastructure and key initiatives across people, processes and practices, Centaur is poised to leverage synergies across the pharmaceutical spectrum and provide end-to-end solutions to prestigious pharmaceutical partners.

Centaur has set growth plans which it hopes to achieve by leveraging integration synergies, sharpening international focus, entering into strategic alliances and In-licensing molecules.